Director, Head of Investigative Toxicology
Nurix · Brisbane, CA +1 place
$240k–$282k/yrOn-site

Earli, Inc.Redwood City, CAPhD
$215k–$235k/yr listed by the employer
On Earli, Inc.’s own careers site (Greenhouse), checked open today.
Summarised from the posting by AI and can be wrong. The full description is the source.
Sign in and add your resume to see which of this job's requirements it shows.
Sign in to check your matchSaved to your account, encrypted. The AI that reads it doesn't keep it or train on it.
From Earli, Inc.’s careers site
Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli’s BioAI approach flips this paradigm: Drugs are produced only where needed—in the tumor, by the tumor, against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.
This was enabled by three core innovations:
Together, these technologies create a new biological control layer, allowing tumors to self-identify and trigger their own targeted immune attack—achieving specificity beyond current targeted or IO therapies.
Earli plans to enter the clinic by mid-2027 with a Phase 1/2 lung cancer trial. The company is backed by a16z, Khosla, Perceptive, Alex Gorsky, Marc Benioff, Breyer, Emerson Collective, Sands Capital and others. The SAB includes Jim Allison (Nobel Laureate, MD Anderson), Bob Langer (Co-founder Moderna, MIT), Phil Greenberg (Co-founder Juno), Amy Abernethy (frm. Principal Deputy FDA Commissioner), Bill Hait (former J&J EVP Oncology R&D), and Alan Ashworth (President UCSF Cancer Center). The leadership team brings deep gene therapy, LNP, CMC and tech experience; CEO Cyriac Roeding previously led a $250M (11x return) exit.
Who You Are
The Position
Earli is currently seeking a Senior Director, In Vivo Pharmacology to oversee and lead the In vivo/Translational biology group. The successful candidate will have a proven track record of successfully initiating and advancing pharmacology and translational science projects across oncology indications from Discovery through IND enabling studies and beyond. She/he will be responsible for working with company scientific leadership for the design and planning of in vivo preclinical studies to characterize the efficacy, PK/PD and safety of Earli’s drug candidates. This position will report to the SVP of Platform R&D.
Primary responsibilities
Education Requirements
Required Experience, Knowledge and Skills
-
Required Experience, Knowledge, and Skills
The base salary for this position is $215k-$235k per year.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
Something wrong with this job? Report it · This flag looks wrong

Nurix · Brisbane, CA +1 place
$240k–$282k/yrOn-site
StrongChecked open todayPosted 16 days ago

Pliant Therapeutics, Inc. · South San Francisco, CA
$290k–$320k/yrFull-timeHybrid
StrongChecked open todayPosted 16 days ago
Altos Labs · San Francisco Bay Area, CA +2 places
$265k–$340k/yrHybrid
StrongChecked open todayPosted 1 month ago

Twist Bioscience · South San Francisco, CA
$189k–$224k/yrOn-site
StrongOpen 2 monthsChecked open todayPosted 2 months ago
Arc Institute · Palo Alto, CA
$264k–$326k/yrHybrid
StrongOpen 2 monthsChecked open todayPosted 2 months ago

Parabilis Medicines · Cambridge, MA
$170k–$200k/yrOn-site
StrongChecked open todayPosted 9 days ago